CCL22 and atherosclerosis: Unlike acute myocardial infarction, where CCL17/CCL22 competition occurs transiently during acute inflammation, our study reveals that this chemokine interplay also exists in atherosclerosis, suggesting a chronic and persistent regulatory mechanism in immune cell recruitment and plaque progression.